Navigation Links
Saol Therapeutics Announces CDC has Updated Information Related to Use and Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
Date:1/14/2019

The Centers for Disease Control (CDC) has updated information related to the use and availability of VARIZIG® (Varicella Zoster Immune Globulin [Human]) for post-exposure prophylaxis of varicella in patients at high-risk, posted on its website (https://bit.ly/2M1l0UR). In the update, the CDC notes that VARIZIG is commercially available from a broad network of specialty distributors in the United States (list available at http://www.varizig.com).

“This update is important for effective distribution and use of VARIZIG for these at-risk patient populations,” said Saol Therapeutics Chief Executive Officer, David Penake, the manufacturer of VARIZIG. “VARIZIG has a strong clinical value in the patient populations it serves, and we are pleased that it is now commercially available from a broad network of US specialty distributors. It is very important that all treating physicians realize that VARIZIG can be easily obtained within 24 hours for high-risk patients following exposure to varicella zoster virus.”

VARIZIG is an FDA-approved immunoglobulin for post-exposure prophylaxis of varicella in high-risk individuals, replacing VZIG (discontinued in 2006). VARIZIG is a hyperimmune product that contains antibodies specific for the varicella zoster virus, which causes the viral infection known as chickenpox.

Clinical Management of Exposure to Varicella-
Despite being considered “benign” in healthy individuals, chickenpox and shingles may be responsible for health complications and death in high-risk patients.(1-4) These patients may be exposed to varicella through chickenpox, or shingles.(4) Exposure to chickenpox is considered serious and can occur in as little as 5 minutes depending on type of exposure.(4) The CDC recommends VARIZIG for people exposed to varicella or herpes zoster who cannot receive varicella vaccine; varicella-zoster immune globulin can prevent varicella from developing or lessen the severity of the disease. Varicella-zoster immune globulin is recommended for people who cannot receive the vaccine and 1) who lack evidence of immunity to varicella, 2) whose exposure is likely to result in infection, and 3) are at high risk for severe varicella.(5) Please see contraindications below in the Important Safety Information.

Evidence of immunity to varicella includes vaccination with varicella vaccine (1 dose =12 months through 3 years of age, 2 doses =4 years of age, adolescents, and adults: 2 doses), birth in the U.S. before 1980 (except for healthcare personnel, pregnant women, and immunocompromised persons), laboratory evidence of immunity or laboratory confirmation of disease, or history of varicella or herpes zoster.(6)

High-risk patients include newborns with mothers having varicella symptoms around delivery; pregnant women without evidence of immunity; hospitalized infants born at or before 28 weeks and weighing less than 2 lbs; and immunocompromised patients without evidence of immunity, such as cancer patients, transplant recipients, and patients with autoimmune or immune-mediated inflammatory disorders.(5,7)

Post-exposure Prophylaxis with VARIZIG® (Varicella Zoster Immune Globulin [Human])-
VARIZIG is a single weight based IM injection intended to reduce the severity of varicella in at-risk patients.(7) In an open-label expanded access protocol of over 500 high-risk individuals that received VARIZIG after exposure to chickenpox or shingles, a low percentage (<10%) developed clinical varicella.(7) VARIZIG should ideally be administered within 96 hours for greatest effectiveness.(7) However, a comparison of the incidence of clinical varicella based on treatment window revealed that treatment between 5 and 10 days post-exposure was no different from treatment within 96 hours.(7) VARIZIG is commercially available from a broad network of specialty distributors in the United States (list available at http://www.varizig.com)

IMPORTANT SAFETY INFORMATION ABOUT VARIZIG (Varicella Zoster Immune Globulin [Human])-
In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, only administer VARIZIG if the expected benefits outweigh the potential risks. Thrombotic events may occur following treatment with VARIZIG and other immune globulin products. Individuals known to have severe, potentially life-threatening reactions to human globulin should not receive VARIZIG or any other immune globulin (Human). Individuals who are deficient in IgA may have the potential for developing IgA antibodies and have severe, potentially life-threatening allergic reactions. Products made from human plasma may carry a risk of transmitting infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent. The most serious adverse drug reactions observed in clinical trials for all subjects and patients include pyrexia, nausea, chills, and vomiting. The most common adverse drug reactions observed in clinical trials for all subjects and patients were injection site pain, headache, chills, fatigue, rash, and nausea.

For further information about VARIZIG, contact Susan Clement, Senior Director, Marketing, Saol Therapeutics, at sclement(at)saolrx.com.

About Saol Therapeutics-
Saol Therapeutics is a commercial specialty pharmaceutical company concentrated on addressing the medical needs of underserved or unserved patient populations and the physicians that treat them.
Further information:
http://www.VARIZIG.com
VARIZIG Full Prescribing Information

SOURCE: Saol Therapeutics http://www.saolrx.com

REFERENCES:
1. Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013;26(4):728-43.
2. Gnann Jr. JW. Antiviral therapy of varicella-zoster virus infections. In: Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 65. Available at: https://www.ncbi.nlm.nih.gov/books/NBK47401/. Accessed September 13, 2018.
3. Cohen JI. Herpes Zoster. N Engl J Med. 2013;369:255-63.
4. American Academy of Pediatrics. Varicella-Zoster Virus Infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018:869-83.
5. Marin M, Bialek SR, Seward JF. Updated recommendations for use of VariZIG — United States, 2013. MMWR Morb Mortal Wkly Rep. 2013;62(28):574–576.
6. Centers for Disease Control and Prevention Yellow Book 2018: Health Information for International Travelers. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/varicella-chickenpox. Accessed September 13, 2018.
7. Saol Therapeutics Inc. VARIZIG Full Prescribing Information. Available from: https://varizig.com/VARIZIG_PI.pdf. Accessed September 13, 2018.

Read the full story at https://www.prweb.com/releases/saol_therapeutics_announces_cdc_has_updated_information_related_to_use_and_availability_of_varizig_varicella_zoster_immune_globulin_human/prweb16026707.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. uBiome Receives Patent for Diagnostics and Therapeutics for Endocrine System Conditions
2. uBiome Receives Patent for Diagnostics and Therapeutics for Microbiome Functional Features
3. Madam Therapeutics Closes €1.1 Million Financing Round to Develop Novel Antibiotics Against Drug Resistant Bacteria
4. Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent
5. Thermo Fisher Scientific Enables Targeted Therapeutics by Utilizing Transcriptomics
6. NEW Ingredient: Euromed SA Partners with Biotherapeutics Inc. to Launch the First Abscisic Acid Nutritional Ingredient to Market
7. Innovations Series Explores Advances in Therapeutics for Treatment and Diagnosis of Disease
8. Open Therapeutics and AuthorAID to Cooperate on Advancing Scientific Knowledge
9. Blue Door Therapeutics Paving the Way to Treat the Opioid Epidemic with $2 Million Dollar Treatment Center in North Scottsdale
10. Coalition Duchenne Congratulates Capricor Therapeutics on Positive Six-Month Results from its Randomized CAP-1002 Phase I/II HOPE Clinical Trial in Duchenne
11. MAP and Lief Therapeutics Partner to Track Anxiety Real-time in Substance Use Disorder Populations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... (PRWEB) , ... October 15, 2019 , ... In 2019, ... began to shut down in late 2018 . Students who started in July ... time, it seemed as if these students would have to start over. Then the ...
(Date:10/11/2019)... ... ... A Topping Out event was hosted today at the construction site of ... Construction. The event celebrated reaching the final height of the structure set to open ... its kind in Texas, STA’s facility will be home to an organ recovery center ...
(Date:10/8/2019)... ... October 08, 2019 , ... Safe Harvest soups ... Meyer, King Sooper, Fry’s, Roundy’s, Smiths and Dillons. , Safe Harvest reinvented classic ... , “Ingredient purity and fresh taste is paramount for us,” says Bryan Boches, ...
(Date:10/8/2019)... ... October 08, 2019 , ... Cognosante has been awarded a ... Affairs Community Care Referrals and Authorizations program. The new task order will allow ... Manager (HSRM), an enterprise-wide system used by community care staff to generate referrals ...
(Date:10/8/2019)... DEL REY, Calif. (PRWEB) , ... October 08, ... ... Confab for laboratory managers, administrators and pathologists, 4medica® President Gregg ... Payment™ is the first-to-market solution reinventing labs orders management-by starting with the ...
Breaking Medicine News(10 mins):
(Date:10/11/2019)... , ... October 11, 2019 , ... Based on data ... a 9 percent increase in deceased organ donors over 2018. Through August 31, 7,786 ... Transplantation Network (OPTN) national database . At this pace, the Association of Organ ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... Cocktail Reception on Thursday, September 26, at the Westchester Country Club in Rye. ... unwavering support of the organization and its mission. , “In Celebration” featured live ...
(Date:10/8/2019)... Pa. (PRWEB) , ... October 09, 2019 , ... “When ... the emotions, frustrations, and the realities of the HEMS world through telling the real ... Helicopter Pilot” is the creation of published author Jay A. Humphrey, an EMS helicopter ...
Breaking Medicine Technology: